Merck is developing a biosimilar of AbbVie’s Humira, and is now advancing with a phase 3 trial that will enroll 406 psoriasis patients in the U.S. and Germany. Pfizer, Novartis and Amgen are working on their own biosimilars of Humira. Drugs based on TNF inhibition, Humira’s mechanism of action, are a popular target for biosimilars, as they can potentially treat a range of diseases including rheumatoid arthritis, ulcerative colitis and Crohn’s disease.

Click here for more.